

Special Issue

Advances in Molecular Pathology and Biology of Soft Tissue and Bone Tumors

Message from the Guest Editors

As you know only too well, the modern management of sarcomas, even by experts, remains a challenge. In fact, we do not currently have a satisfactory therapeutic weapon for management, both outside of and in addition to surgery. We also too often face a lack of markers to decide which patients can potentially benefit from possibly effective treatments, at least in selected patients. Could this challenge be due to our lack of knowledge of this disease, which has a terribly poor prognosis? We are pleased to invite you to submit your papers to this Special Issue to increase our knowledge in the oncogenesis of sarcomas, allowing us to move toward better patient management. This Special Issue aims to gather the current research in the field of sarcoma research, from molecular pathology to immune and cellular therapies, including sarcoma genetics, biology, and metabolism, cancer stem cells, differentiation, circulating tumor cells studies, spontaneous dog/cat models, and pre-clinical research. For further reading, please visit the [Special Issue](#) website.

Guest Editors

Dr. Frederic Chibon

Prof. Dr. Anne Gomez-Brouchet

Dr. Philippe Rochemaix

Dr. Franck Tirede

Deadline for manuscript submissions

closed (30 June 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/121132

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)